Amgen and Gilead deliver lacklustre early clinical results with AMG 355 and denikitug respectively.
ApexOnco Front Page
Recent articles
Lilly makes its second in vivo Car-T acquisition, buying the privately held Kelonia for $3.25bn.
A 5% response rate with IMA402 monotherapy seems unlikely to turn heads.
The group touts a 72% ORR with SCIB1, but full Scope data have been pushed back into 2025.
NXP800 yields neither severe thrombocytopenia, nor any responses.
For $500m the big pharma group secures LaNova's anti-VEGF x PD-1 antibody.
A year after paying $55m to license Biotheus’s PD-L1/VEGF, BioNTech is going all in for $800m.
First-gen drugs feature in BCL-2 combos, while Jaypirca and BTK degraders apply extra pressure.
